PRESENTATION
Q1 2023 — Presentation
Q1 2023PDF · 30 pages2.0 MB
Merck Q1 2023 Earnings April 27, 2023 -- 1 of 30 -- Agenda 2 Strategy and Business Update Rob Davis Chairman and Chief Executive Officer Question & Answer Session Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories -- 2 of 30 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 30 -- Strategy & Business Update Rob Davis Chairman and Chief Executive Officer -- 4 of 30 -- Delivered on our key strategic priorities in 1Q 2023 5 Advanced the pipeline to meet patient unmet need Achieved strong commercial and financial performance Executed on strategic business development to enhance pipeline Created long-term value for patients and shareholders -- 5 of 30 -- 6 Merck continues to advance science-led strategy through acquisition of Prometheus Biosciences 6 Potentially transformational, first-in-class, late-stage candidate, in a disease area with significant unmet medical need + Opportunity to potentially transform standard of care for certain patients suffering from debilitating autoimmune diseases through precision medicine approach Multi-billion dollar commercial opportunity with potential to drive long-term revenue and earnings growth well into the next decade Diversifies portfolio and enhances our sustainable innovation engine -- 6 of 30 -- Very significant 1Q sales and underlying earnings growth1 7 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Merck does not exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre- approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Full year 2022 non-GAAP results include $690 million or $0.22 of such charges. Full year 2021 non-GAAP results include $1.7 billion or $0.65 of such charges. 1Q23 non-GAAP results include $1.4 billion or $0.52 of such charges. For 2023, outlook does not assume the proposed acquisition of Prometheus or any additional significant potential business development transactions. 3. GAAP EPS of $1.11. 4. 2023 GAAP guidance range of $5.85 to $5.97. $41.5B +6% $48.7B +17% GUIDANCE RANGE $57.5B-$58.5B $14.5B -9% +15% ex-Exchange, ex-LAGEVRIO 1Q Worldwide Sales $1.40 -35% 1Q Non-GAAP EPS2,3 2021 2022 2023 $48.7B +17% 2021 2022 2023 $5.37 Full Year Sales Full Year Non-GAAP EPS2 $59.3B +22% $7.48 GUIDANCE RANGE $57.7B - $58.9B GUIDANCE RANGE $6.88 - $7.00 -- 7 of 30 -- Advancing and augmenting deep pipeline in 1Q 8 Cardiovascular Oncology • Presented detailed results from Phase 2b trial evaluating KEYTRUDA in combination with mRNA-4157/V940, an investigational individualized neoantigen therapy, with partner Moderna, for the adjuvant treatment of patients with stage III/IV melanoma following complete resection at AACR • Announced positive topline results from Phase 3 KN-671 trial evaluating KEYTRUDA regimen as neoadjuvant/adjuvant treatment in patients with resectable stage II, IIIA or IIIB NSCLC • Presented positive Phase 3 data from the STELLAR trial evaluating sotatercept at ACC.23/WCC • Presented positive Phase 2 data for MK-0616 at ACC.23/WCC • Hosted investor event to discuss data and provide overview of broader research efforts in cardiology Translating breakthrough science into medicines and vaccines that save and improve lives Building a sustainable innovation engine -- 8 of 30 -- Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer -- 9 of 30 -- Strong underlying Q1 sales growth across Human Health and Animal Health 10 Merck WORLDWIDE SALES1,2 $14.5B-9% growth +11% ex-LAGEVRIO3 +15% ex-exchange, ex-LAGEVRIO4 $12.7B -10% growth +14% ex-LAGEVRIO3 +18% ex-exchange, ex-LAGEVRIO4 Human Health $1.5B +1% growth +5% ex-exchange Animal Health 1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue 3. Excludes Lagevrio sales of $392 million in 1Q23 and $3.2 billion in 1Q22. 4. Excludes Lagevrio sales of $392 million in 1Q23 and $3.2 billion in 1Q22 and foreign exchange -- 10 of 30 -- Oncology: KEYTRUDA drives strong growth 11 Growth rates exclude the impact of foreign exchange. • KEYTRUDA sales of $5.8B increased 24% year-over-year, driven by strong global demand in metastatic cancers and increased uptake from earlier-stage indications – In the U.S., growth of 25% reflects strong uptake across in earlier-stage cancers such as TNBC, as well as certain types of renal cell carcinoma and melanoma – Ex-U.S., 22% increase driven by continued global uptake in metastatic RCC as well as earlier-stage cancers, including high-risk early stage TNBC $4.2B +20% $3.4B +31% $5.3B +30% 1Q21 1Q22 1Q23 $4.8B +27% $3.9B +16% $5.8B +24% -- 11 of 30 -- Oncology: Solid performance across broad portfolio • Lynparza 1 sales grew 8% driven primarily by increased demand in key European markets in certain patients with ovarian cancer • Lenvima 2 sales grew 5% due to increased uptake in advanced RCC in key European markets $248M +34% $178M +62% $275M +17% $181M +15% $151M +57% $231M +33% 12 Increase/decrease in sales exclude the impact of foreign exchange. 1 In collaboration with AstraZeneca; 2 In collaboration with Eisai 1Q21 1Q22 1Q23 1Q21 1Q22 1Q23 $266M +20%$228M +51% $275M +8% $227M +77% $130M -1% $232M +5% -- 12 of 30 -- Vaccines: GARDASIL growth driven by strong international demand 13 • GARDASIL sales of $2.0B increased 43% year-over-year primarily driven by strong underlying demand outside the U.S., particularly China, as well as increased supply – China growth also benefitted from an acceleration of shipments from 2H to 1H to ensure availability of product to meet heightened demand following the approval of the expanded indication of GARDASIL 9 for girls and women 9 to 45 years of age • Strong ongoing pediatric launch of VAXNEUVANCE is tracking with expectations $1.2B +78% $656M -24% $1.7B +40% 1Q21 1Q22 1Q23 $1.5B +60% $917M -20% $2.0B +43% Growth rates exclude the impact of foreign exchange. -- 13 of 30 -- Hospital: Strong global demand across key products 14 • BRIDION sales of $487M increased 27% primarily due to greater share among neuromuscular blockade reversal agents • PREVYMIS sales grew 44% driven by continued strong global demand $387M +67% $224M -18% $426M +15% 1Q21 1Q22 1Q23 $395M +20%$340M +11% $487M +27% $93M +41%$63M +67% $103M +18% 1Q21 1Q22 1Q23 $94M +20% $82M +31% $129M +44% Growth rates exclude the impact of foreign exchange. -- 14 of 30 -- Animal Health: Solid growth driven by livestock 15 • Animal Health sales increased 5% to $1.5B, reflecting strong demand across livestock portfolio, as well as strategic price actions – Livestock growth of 8% due to strong performance in ruminants and poultry products – Companion Animal results reflect increased sales of Bravecto, partially offset by supply challenges for certain vaccines $1.5B +27% $1.1B +3% $1.5B +5% 1Q21 1Q22 1Q23 $1.5B +9% $1.4B +15% $1.5B +5% Growth rates exclude the impact of foreign exchange. -- 15 of 30 -- Q1 2023 continuing operations non-GAAP financial results summary 1 Q1 2023 Q1 2022 Change Change Ex-FX Sales $14.5 $15.9 -9% -5% Non-GAAP Gross Margin 76.9% 70.7% +6.1pts +5.9pts Non-GAAP Operating Expenses 2 $6.7 $4.8 +40% +42% Non-GAAP Tax Rate 20.4% 14.0% +6.4pts N/A Non-GAAP EPS3 $1.40 $2.14 -35% -30% $ in billions, except EPS amounts 16 1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release. 2. For Q1 Non-GAAP results include $1.4 billion of R&D expense, or an estimated $0.52 of negative impact to EPS, related to an asset acquisition, and collaboration and licensing agreement. 3. Q1 2023 GAAP EPS of $1.11. -- 16 of 30 -- Merck updated full-year 2023 guidance 1. GAAP Gross Margin Rate: ~73% 2. GAAP Operating Expenses: $23.5 to $24.3 billion 3. GAAP Tax Rate: ~17-18% 4. The GAAP to non-GAAP reconciliation is available in Merck’s Q1 2023 earnings release 5. Merck includes expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results 6. The proposed Prometheus Biosciences acquisition is anticipated to result in a one-time charge of approximately $10.3 billion recorded to both GAAP and non-GAAP R&D expenses in 2023 or approximately $4.00 per share, as well as an approximate $0.25 negative impact on EPS in the first 12 months following close. 17 Prior Guidance Updated Guidance Key Assumptions Revenue $57.2B to $58.7B -4% to -1% (-2% to +1% ex-FX) $57.7B to $58.9B -3% to -1% (-1% to +1% ex-FX) • Includes approximately $1B of LAGEVRIO revenue • Ex-LAGEVRIO, growth of 6% to 8% (8 to 10% ex-FX) • Assumes ~2% FX headwind Non-GAAP Gross Margin Rate 1 ~77.0% ~77.0% Non-GAAP Operating Expenses2,5,6 $23.1B to $24.1B $23.3B to $24.1B • Includes $1.4B of upfront R&D expense related to acquisition of Imago Biosciences and expansion of collaboration with Kelun Biotech • Does not include the proposed acquisition of Prometheus Biosciences6 Other (Income) / Expense ~$250M of income ~$250M of income Tax Rate 3 ~17.0%-18.0% ~17.0%-18.0% Shares Outstanding ~2.55B ~2.55B • Assumes modest share repurchase GAAP EPS $5.86 to $6.01 $5.85 to $5.97 Non-GAAP EPS4,5,6 $6.80 to $6.95 $6.88 to $7.00 • Includes $0.52 of charges related to an acquisition, and significant collaborations and licensing agreement • Assumes ~4% FX headwind -- 17 of 30 -- Key modeling considerations KEYTRUDA GARDASIL • In the U.S., exceptional growth in prior quarters is expected to moderate as strong uptake from recently launched indications, particularly in earlier-stage cancers, is annualized • Ex-U.S., expect strong volume growth to be partially offset by pricing headwinds, particularly in key European markets 18 • Expect strong growth driven by robust global demand, particularly in ex-U.S. markets • Expect an acceleration of full year growth in 2023 relative to 2022, though not at the same rate of growth as in Q1 2023 -- 18 of 30 -- 19 Continue to prioritize investments in our pipeline and business to realize value of near- and long-term opportunities $3.4 $1.0 $1.9 $1.9 $0.1 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase $ Billions1 1. Reflects Q1 spend Remain committed to balanced capital allocation strategy Capital allocation order of priority -- 19 of 30 -- Research Update Dr. Dean Li President, Merck Research Laboratories -- 20 of 30 -- Driving value for patients and shareholders by progressing our pipeline 21 Key regulatory milestones since the last earnings call: Key data & clinical advancements since the last earnings call: • In the U.S., the FDA: o Converted from accelerated to full approval indication for KEYTRUDA in patients with unresectable or metastatic microsatellite instability-high (MSI- H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment option o Granted accelerated approval of KEYTRUDA in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy based on KEYNOTE-869 o Accepted sBLA for KEYTRUDA in combination with chemotherapy for the treatment of HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma regardless of PD-L1 expression based on KEYNOTE-859 o Granted Breakthrough Therapy Designation for mRNA-4157/V940 in combination with KEYTRUDA the adjuvant treatment of high-risk melanoma following complete resection o Approved expanded administration option for intramuscular route of administration for the MMRV family of vaccines, M-M-RII, VARIVAX and ProQuad o Accepted priority review for the sNDA for PREVYMIS for prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk • In Europe, the EMA: o Granted Priority Medicines scheme designation for mRNA-4157/V940 in combination with KEYTRUDA for the treatment of high-risk adjuvant melanoma following complete resection • In Japan, the MHLW: o Approved LAGEVRIO for the treatment of COVID-19 1. In collaboration with AstraZeneca 2. In collaboration with Moderna 3. In collaboration with Gilead • Presented results of the Phase 3 STELLAR trial evaluating sotatercept, a novel investigational activin signaling inhibitor biologic, in combination with stable background therapy for the treatment of adult patients with pulmonary arterial hypertension and the Phase 2b clinical trial evaluating MK-0616, an investigational oral PCSK9 candidate, for adult patients with hypercholesterolemia at ACC.23/WCC • Presented final results of key secondary overall survival endpoint from Phase 3 PROpel trial evaluating Lynparza1 in combination with abiraterone and prednisone or prednisolone at 2023 ASCO Genitourinary Cancers Symposium • Announced Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA in combination with chemotherapy as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer met one of its dual primary endpoints of event-free survival • Announced results of Phase 3 NRG-GY018 trial evaluating KEYTRUDA in combination with chemotherapy then continued as a single agent for the treatment of patients with stage III-IV or recurrent endometrial carcinoma whose cancer was either mismatch repair proficient or mismatch repair deficient • Announced results of Phase 2/3 KEYNOTE-483 trial evaluating KEYTRUDA in combination with chemotherapy as first-line treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma met its primary endpoint of overall survival • Announced results of Phase 2 KEYNOTE-942 trial evaluating KEYTRUDA in combination with mRNA-4157/V9402 for the treatment of high-risk adjuvant melanoma following complete resection at AACR • Opened enrollment for new Phase 3 clinical trials with investigational once-daily islatravir in combination with doravirine and Phase 2 clinical trial with once-weekly islatravir in combination with lenacapavir3 for treatment of HIV-1 infection -- 21 of 30 -- Making tangible advancements in our cardiovascular pipeline Sotatercept MK-0616 • Presented Phase 3 results from the STELLAR trial • Substantial improvement of 40.8 meters in 6MWD at Week 24 • Met 8 out of 9 secondary endpoints including: o 84% reduction in risk of death or clinical worsening events1 • Advancing broad program, including Phase 3 HYPERION, ZENITH, SOTERIA and Phase 2 CADENCE studies • Presented Phase 2b results • Reduction of LDL-cholesterol levels from 41.2 up to 60.9 % vs placebo, across 4 doses in study • Eighty to 90% of patients receiving MK-0616 were able to reach their LDL-C goals • Defined path toward providing a therapy that could achieve broad global access • Initiating multiple Phase 3 studies including a cardiovascular outcomes trial 22 1. TTCW is time to clinical worsening or death (defined by death of any cause or specified non-fatal clinical worsening events); sotatercept plus stable background therapy reduced the risk of clinical worsening or death by 84% compared to placebo plus background therapy with a median follow-up of 32.7 weeks (HR=0.16 [95% CI, 0.08-0.35]; p<0.001 -- 22 of 30 -- 23 Developing treatments for earlier stages of cancer remains a key area of focus and execution At AACR, in collaboration with Moderna, announced detailed results from Phase 2b KEYNOTE-942 investigating the combination of KEYTRUDA and MRNA-4157/V490, an individualized neoantigen therapy The 18-month RFS rate was 78.6% (95% CI, 69.0-85.6) and 62.2% (95% CI, 46.9-74.3) in the combination and control arms, respectively Making progress in the treatment of earlier stage NSCLC through multiple clinical trials APPROVED KEYNOTE-091: Received FDA approval for KEYTRUDA for adjuvant treatment of adult patients with stage IB (T2a >=4 cm), II or IIIA NSCLC following resection and platinum-based chemotherapy PHASE III KEYNOTE-867: Evaluating KEYTRUDA in patients undergoing stereotactic body radiotherapy with unresected stage I or II NSCLC KEYLYNK-012: Evaluating KEYTRUDA in combination with Lynparza1 in stage III disease 1. In collaboration with AstraZeneca FILED KEYNOTE-671: Announced positive top line results for KEYTRUDA with platinum doublet chemotherapy as neoadjuvant followed by adjuvant therapy for patients with resectable stage II, IIIA and IIIB NSCLC KEYTRUDA Immunotherapy that increases the ability of the body’s immune system to help detect and fight tumor cells mRNA-4157/V940 Designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumor -- 23 of 30 -- 24 Advancing our broader oncology portfolio Adenocarcinoma Prostate Women’s Cancers Antibody Drug Conjugates 1. In collaboration with Orion • NRG-GY018: Announced positive data for KEYTRUDA in combination with chemotherapy for 1L treatment of patients with stage III to IV of recurrent endometrial carcinoma • Building upon approvals based on KEYNOTE-146, KEYNOTE-775 and KEYNOTE-158 in endometrial cancer • KEYNOTE-859: FDA accepted application for KEYTRUDA in combination with chemotherapy in HER2- negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma • Remain committed to addressing this area of significant unmet patient need • Planning to initiate Phase 3 trials for MK-5684 1, a novel oral non-steroidal inhibitor of CYP-11A1, by the end of 2023 • KEYNOTE-869: Announced accelerated approval of KEYTRUDA, in combination with enfortumab vedotin, an anti-body drug conjugate, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy • Kelun-Biotech: Planning to initiate multiple Phase 3 trials for MK-2870, a TROP-2 targeting ADC, as monotherapy and in combination with KEYTRUDA -- 24 of 30 -- 25 Expanding our broader pipeline and portfolio Infectious Disease Immunology + • HIV – Enrolling multiple new Phase 3 studies for once-daily islatravir in combination with doravirine – Resumed the Phase 2 study of an oral once-weekly combination treatment regimen of islatravir and Gilead’s lenacapavir • COVID-19 – Received full approval for LAGEVRIO for the treatment of COVID-19 by the Ministry of Health Labor and Welfare in Japan • Proposed acquisition of Prometheus Biosciences augments and accelerates ongoing research efforts in immunology • PRA023 is a potential first-in-class late-stage clinical candidate with positive Phase 2 results in ulcerative colitis and Crohn’s Disease • Suite of immunology pipeline compounds including PRA052 • Deep genetic and biological insights from Prometheus 360 Data Science Platform -- 25 of 30 -- Q&A Rob Davis Chairman & Chief Executive Officer Caroline Litchfield Chief Financial Officer Dr. Dean Li President, Merck Research Laboratories Peter Dannenbaum Vice President, Investor Relations -- 26 of 30 -- Appendix 27 -- 27 of 30 -- Q1 2023 GAAP financial results summary 28 Q1 2023 Q1 2022 Change Change Ex-FX Sales $14.5 $15.9 -9% -5% Operating Expenses $6.8 $4.9 +38% +40% Tax Rate 22.6% 11.4% +11.2pts N/A GAAP EPS $1.11 $1.70 -35% -30% $ in billions, except EPS amounts -- 28 of 30 -- $11.4 $4.4 $7.1 $3.5 $0.1 $0 $3 $6 $9 $12 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation: Trailing twelve months ~$18B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$10B in the U.S. Billions $1.76 $1.80 $1.84 $1.88 $1.92 $2.20 $2.44 $2.60 $2.76 $2.92 $1.40 $1.70 $2.00 $2.30 $2.60 $2.90 $3.20 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Dollars per share +2% +2% +2% +2% +2% +11% +15% +7% Over the past 12 months Capital investments 2022 to 2026 Commitment to the dividend 29 Well positioned balance sheet with capacity to fund additional value-enhancing business development opportunities +6% Order of priority +6% E 1. Includes payments reflected in operating cash flow 1 -- 29 of 30 -- Phase 2 Phase 3 Under regulatory review Oncology V181 Dengue Fever Virus Vaccines Infectious diseases MK-8189 4 Schizophrenia Neuroscience Gefapixant (MK-7264) Cough (US, EU) General medicine General medicine As of April 27, 2023 V114 Pneumococcal Vaccine, pediatric (JPN) Vaccines Infectious diseases Oncology Oncology MK-1942 Treatment Resistant Depression MK-6024 (efinopegdutide) NASH MK-8591B (islatravir+MK-8507) 1 HIV-1 Infection MK-8591D (islatravir+lenacapavir) 2 HIV-1 Infection KEYTRUDA (MK-3475) Biliary CSCC (EU) Hepatocellular (EU) Mesothelioma Ovarian SCLC MK-1026 (nemtabrutinib) Hematological Malignancies MK-1308A (quavonlimab +pembrolizumab) RCC MK-7684A (vibostolimab +pembrolizumab) Melanoma NSCLC SCLC MK-4280A (favezelimab +pembrolizumab) CRC Hematological Malignancies LENVIMA (MK-7902) Esophageal Gastric HNSCC NSCLC LYNPARZA (MK-7339) NSCLC SCLC WELIREG (MK-6482) RCC TUKYSA (MK-7119) Breast CRC MK-3475 (pembrolizumab subcutaneous) NSCLC MK-3475A (pembrolizumab +hyaluronidase) NSCLC MK-8591A (doravirine+islatravir) 2 HIV-1 Infection LAGEVRIO (MK-4482) 3 COVID-19 antiviral KEYTRUDA (MK-3475) 2L HCC (US) LA Merkel Cell (US) Adjuvant NSCLC (EU) 1L HER2- Gastric (US, EU) Resectable NSCLC (US, EU) B-Cell Lymphoma (JPN) LYNPARZA (MK-7339) Metastatic 1L Prostate (US, JPN) MK-0616 Hypercholesterolemia MK-2060 Thrombosis MK-5475 Pulmonary Arterial Hypertension MK-7962 (sotatercept) Pulmonary Hypertension due to Left Heart Disease Cardiovascular MK-4830 CRC Esophageal Melanoma NSCLC Ovarian RCC SCLC MK-5684 Prostate MK-5890 (boserolimab) NSCLC SCLC MK-6440 (ladiratuzumab vedotin) Breast Esophageal Gastric HNSCC Melanoma NSCLC Prostate SCLC MK-2870 Neoplasm Malignant KEYTRUDA (MK-3475) Advanced Solid Tumors Prostate MK-3543 (bomedemstat) Myeloproliferative Disorders MK-4280 (favezelimab) NSCLC MK-4280A (favezelimab+pembroli zumab) Bladder Esophageal Melanoma RCC SCLC WELIREG (MK-6482) Biliary Certain VHL tumors (EU) CRC Endometrial Esophageal HCC Pancreatic Rare Cancers LYNPARZA (MK-7339) Advanced Solid Tumors LENVIMA (MK-7902) Biliary Melanoma Pancreas Prostate SCLC mRNA-4157/V940 Melanoma MK-7684A (vibostolimab +pembrolizumab) Biliary Bladder Breast Cervical CRC Endometrial Esophageal Gastric HCC HNSCC Hematological Malignancies Ovarian Prostate TUKYSA (MK-7119) Advanced Solid Tumors Bladder Biliary Cervical Endometrial Gastric NSCLC MK-0482 NSCLC MK-1308 (quavonlimab) NSCLC MK-1308A (quavonlimab +pembrolizumab) CRC HCC Melanoma SCLC MK-2140 (zilovertamab vedotin) Bladder Breast Gastric Hematological Malignancies NSCLC Ovarian Pancreas Broad and innovative pipeline to solve significant unmet medical needs 30 Vaccines MK-1654 (clesrovimab) Respiratory Syncytial Virus (RSV) 1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials 3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma 5 Requested re-examination of EU MAA following CHMP major objection of data to support market authorization MK-7962 (sotatercept) Pulmonary Arterial Hypertension Cardiovascular Infectious diseases LAGEVRIO (MK-4482) 5 COVID-19 antiviral (EU) V116 Pneumococcal vaccine, adult Hospital PREVYMIS (MK-8228) Prophylaxis of CMW in kidney transplant patients -- 30 of 30 --